NR4A1 and breast cancer: Extending the duration of endocrine therapy from 5 to 10 years has been demonstrated to provide consistent but modest benefits to breast cancer patients in the range of 1% to 5% in patients with hormone receptor-positive (HR+) early stage breast cancer [1, 2].